Corporate Overview

SYGNIS is a German-Spanish stocklisted company devoted to the development of novel, superior tools for molecular biology that play key roles in changing the way genomic and proteomic research is done today. Demand for such tools is high in the fast-growing DNA and protein analysis markets.

SYGNIS has developed a well balanced product portfolio based on proprietary technology:

• The flagship product is QualiPhi®, a novel DNA polymerase licensed to Qiagen. QualiPhi® is a superior version of Phi29 DNA polymerase used for amplifying very small amounts of DNA. This is a key entry point needed to make samples accessible for downstream analyses such as sequencing or hybridization techniques and used in areas such as genetic counseling, pathology, forensics, and research
• Next to this the company is developing a revolutionary new DNA Primase / Polymeraseand proteomic techniques that enable novel screening assays and protein-protein interaction research (Double Switch).

The world of medicine is shifting from the traditional "one size fits all" approach to one where the genetic profile of patients is used to make the most effective clinical decisions for individual patients – a concept known as Personalized Medicine.

Personalized Medicine is a new important driver for the polymerase market. Personalized Medicine tries to tailor medical diagnostics and treatments to the individual characteristics of the patients, i.e., their genetic repertoire.

Automated systems for sequencing DNA or spot-checking for genetic variation at low costs are essential to progress in both research and clinical applications, and this is pushing forward the need for new polymerases adapted to the so called Next Generation Sequencing equipments.

In particular, SYGNIS' polymerases enable a wide range of applications for DNA amplification, repair, sequencing, detection and modification of genetic targets of clinical value. The company is thus ideally suited to play a major part in the global effort to discover the genetic markers of disease, and their cost effective detection, in individual patients to deliver optimized treatments.